Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$44.5M-195%-$46.14M-$27.08M-13.5%-$12.3M+59.4%$46.89M+247%
$2.03M-0.9%$2.09M+1.3%$2.1M-0.4%$2.13M+3.2%$2.05M+8.0%
$5.95M+12.3%$4.31M-3.6%$4.36M+1.9%$4.89M+8.7%$5.3M+8.7%
-$37.37M+17.9%-$43.01M-133%$100.43M+578%-$34.72M-25.0%-$45.49M-19.2%
$1.87M+17.7%$767K+319%$651K+63.2%$1.7M-16.2%$1.59M+14.7%
-$261M-160%-$65.07M-111%-$100.23M-1,117%
$328.34M+2,345,150%$29.62M+4,772%$348K+2,220%$365K-99.6%$14K-94.3%
$29.97M+121%-$78.46M-180%-$9.03M-$145.71M-419%
-$39.24M+16.7%-$43.78M-134%$99.78M+566%-$36.42M-22.2%-$47.08M-19.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monte Rosa Therapeutics, Inc. generate?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.